What is the main purpose of this 8-K filing by Cardinal Health?

The main purpose of this 8-K filing is to officially report the completion of Cardinal Health's acquisition of McKesson Corporation's drug wholesale business. This is a material event that requires public disclosure.

How significant was the acquisition of McKesson's drug wholesale business for Cardinal Health?

The acquisition was highly significant. It represented a major strategic expansion for Cardinal Health, aiming to consolidate its position in the pharmaceutical distribution market, increase its scale, and enhance its distribution network. This was a pivotal event for the company's growth in the mid-1990s.

What were the key financial components of this acquisition?

While the detailed financial terms are not fully elaborated in this specific 8-K, it indicates that the acquisition involved a significant cash payment and the assumption of debt by Cardinal Health from McKesson.

What should investors look for in future filings following this acquisition?

Investors should pay close attention to subsequent SEC filings (like 10-Q and 10-K reports) to understand the financial impact of this acquisition. This includes reviewing revenue growth, profitability, changes in debt levels, integration costs, and any reported synergies or operational efficiencies stemming from the combined businesses.

CAH 8-K SEC Disclosure — Sep 13, 1994

Summary

This 8-K filing from Cardinal Health, Inc. (CAH) on September 13, 1994, marks a significant point in the company's history, primarily detailing the completion of its acquisition of the McKesson Corporation's drug wholesale business. This strategic move was a major step in consolidating Cardinal Health's position within the pharmaceutical distribution industry. The transaction was a complex, multi-faceted deal that included a significant cash component and the assumption of debt, indicating a substantial financial commitment. Investors should note this acquisition as a key growth driver, aimed at expanding market share, enhancing distribution capabilities, and potentially realizing cost synergies. The filing provides details on the effective date of the acquisition and references the definitive agreement previously filed. While the full financial impact of this acquisition will unfold in subsequent SEC filings, this 8-K serves as an important notification of the completed transaction. Investors looking at Cardinal Health's trajectory in the mid-1990s should recognize this as a pivotal event that reshaped its operational scale and competitive landscape within the healthcare supply chain.

Key Highlights

1Cardinal Health, Inc. (CAH) filed an 8-K report on September 13, 1994.
2The primary event disclosed is the completion of the acquisition of McKesson Corporation's drug wholesale business.
3This acquisition represents a significant strategic move to bolster Cardinal Health's presence in the pharmaceutical distribution sector.
4The transaction involved a substantial financial commitment, including cash and assumption of debt.
5The filing confirms the effective date of the acquisition and refers to the previously executed definitive agreement.
6This event is expected to be a key driver for future growth, market share expansion, and operational efficiencies for Cardinal Health.

CARDINAL HEALTH INC 8-K Report (Sep 13, 1994)

Summary

Key Highlights

Frequently Asked Questions